Tadakazu Hisamatsu

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

Bruce E. Sands, William J. Sandborn, Remo Panaccione et al. · New England Journal of Medicine · 2019 · 1.1K citations · Full text

CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells

Tadakazu Hisamatsu, Manabu Suzuki, Hans-Christian Reinecker et al. · Gastroenterology · 2003 · 631 citations

Inflammation, Dysbiosis, Antibacterial Factor +10

Unique CD14+ intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-γ axis

Nobuhiko Kamada, Tadakazu Hisamatsu, Susumu Okamoto et al. · Journal of Clinical Investigation · 2008 · 589 citations · Full text

IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease

Taku Kobayashi, Shosuke Okamoto, Tadakazu Hisamatsu et al. · Gut · 2008 · 554 citations

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

Geert D’Haens, Remo Panaccione, Filip Baert et al. · The Lancet · 2022 · 362 citations

Rheumatology, Induction Therapy, Immunology +9